Commentary - (2025) Volume 13, Issue 1
Received: 28-Jan-2025, Manuscript No. JCMG-25-165723;
Editor assigned: 30-Jan-2025, Pre QC No. P-165723;
Reviewed: 13-Feb-2025, QC No. Q-165723;
Revised: 20-Feb-2025, Manuscript No. R-165723;
Published:
27-Feb-2025
, DOI: 10.37421/2472-128X.2025.13.319
Citation: Nicole, Abdon. "Prognostic Value of Mutations in Key Cancer Driver Genes in Advanced Lung Adenocarcinoma." J Clin Med Genomics 13 (2025): 319.
Copyright: © 2025 Nicole A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
In this study, we examine the association between mutations in key cancer driver genes and clinical outcomes in a large cohort of patients with advanced lung adenocarcinoma. Using publicly available datasets, including The Cancer Genome Atlas (TCGA) and clinical-genomic data from institutional cohorts and commercial platforms, we assess the mutational status of frequently altered genes such as TP53, KRAS, EGFR, STK11, KEAP1, and ALK. These genes were selected based on their known involvement in lung adenocarcinoma pathogenesis and therapeutic relevance. We analyze Overall Survival (OS), Progression-Free Survival (PFS), and response to standard therapies in relation to mutation status, while adjusting for key clinical variables such as age, smoking history, stage, and treatment type [3,4].
The analysis reveals distinct prognostic patterns associated with specific gene mutations. TP53 and STK11 mutations are significantly associated with worse overall survival, suggesting a more aggressive disease phenotype. In contrast, patients with EGFR mutations tend to exhibit improved survival, particularly when treated with Tyrosine Kinase Inhibitors (TKIs), reflecting the therapeutic sensitivity conferred by these alterations. KRAS mutations, especially in combination with co-mutations in STK11 or KEAP1, are linked to poorer outcomes and reduced response to immunotherapy, underscoring the need for combination treatment strategies in these subgroups. Furthermore, gene mutation combinations appear to be more predictive of prognosis than single-gene alterations alone, highlighting the value of integrated genomic profiling [5].
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Journal of Clinical & Medical Genomics received 391 citations as per Google Scholar report